Abstract
In 2008, the Netherlands Association of Gastroenterologists and Hepatologists (Nederlands Vereniging van Maag-Darm-Leverartsen) published the Dutch national guidelines for the treatment of chronic hepatitis B virus infection. New insights into the treatment of chronic hepatitis B with relevance for clinical practice have been adopted in these concise, revised guidelines. The most important changes include the choice of initial antiviral therapy, licensing of tenofovir for the treatment of chronic hepatitis B and the management of antiviral resistance.
MeSH terms
-
Adenine / administration & dosage
-
Adenine / analogs & derivatives*
-
Adenine / standards
-
Adenine / therapeutic use
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / standards
-
Antiviral Agents / therapeutic use
-
Drug Approval*
-
Drug Resistance, Viral / drug effects*
-
Female
-
Guanine / administration & dosage
-
Guanine / analogs & derivatives*
-
Guanine / standards
-
Guanine / therapeutic use
-
Hepatitis B, Chronic / complications
-
Hepatitis B, Chronic / drug therapy*
-
Humans
-
Infectious Disease Transmission, Vertical / prevention & control
-
Lamivudine / standards
-
Lamivudine / therapeutic use
-
Milk, Human / drug effects
-
Netherlands
-
Nucleosides / administration & dosage
-
Nucleosides / therapeutic use
-
Organophosphonates / administration & dosage
-
Organophosphonates / standards
-
Organophosphonates / therapeutic use*
-
Practice Guidelines as Topic*
-
Pregnancy
-
Pregnancy Complications, Infectious / drug therapy*
-
Renal Insufficiency / drug therapy
-
Renal Insufficiency / etiology
-
Telbivudine
-
Tenofovir
-
Thymidine / analogs & derivatives
-
Thymidine / standards
-
Thymidine / therapeutic use
Substances
-
Antiviral Agents
-
Nucleosides
-
Organophosphonates
-
Telbivudine
-
Lamivudine
-
entecavir
-
Guanine
-
adefovir
-
Tenofovir
-
Adenine
-
Thymidine